AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17484080 — intervention group
Group type: COMPARATOR
Intervention: Intravenous indomethacin
Number of subjects: 21
Study 17484080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension
Number of subjects: 21
Study 15047685 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (<10% carbohydrate)
Number of subjects: 13
Study 15047685 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<30% fat)
Number of subjects: 13
Study 15047685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study 15047685 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Number of subjects: 13
Study 11818602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with adjunct hypnosis
Number of subjects: 161
Study 11818602 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous conscious sedation
Number of subjects: 161
Study 9470469 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a wobble board for 12 weeks
Number of subjects: 48
Study 9470469 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 48
Study 9470469 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a wobble board
Number of subjects: 48
Study 7610512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 0
Study 7610512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Number of subjects: 0
Study 2378717 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagography
Number of subjects: 182
Study 2378717 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagoscopy
Number of subjects: 182
Study 365126 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study 365126 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 30616547 — intervention group
Group type: EXPERIMENTAL
Intervention: BITS7201A (300 mg SC, 750 mg IV, 150 mg SC, 300 mg SC, 600 mg SC)
Number of subjects: 41
Study 30616547 — intervention group
Group type: EXPERIMENTAL
Intervention: BITS7201A (150 mg SC, 300 mg SC, 600 mg SC)
Number of subjects: 41
Study 30616547 — intervention group
Group type: EXPERIMENTAL
Intervention: BITS7201A
Number of subjects: 41
Study 28183284 — intervention group
Group type: EXPERIMENTAL
Intervention: QbTest
Number of subjects: 86
Study 25287767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump therapy
Number of subjects: 600
Study 25287767 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without intra-aortic balloon pump
Number of subjects: 600
Study 23820879 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program for 12 months
Number of subjects: 86
Study 23820879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 86
Study 21188406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole IR (up to 4 mg/day)
Number of subjects: 231
Study 21188406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 21188406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole IR
Number of subjects: 231
Study 19810583 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin exposure during gross anatomy laboratory dissection class (2 hours)
Number of subjects: 20
Study 17294136 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PAD intervention (individual meeting with a trained facilitator)
Number of subjects: 469
Study 17294136 — intervention group
Group type: COMPARATOR
Intervention: Control group (written materials about PADs)
Number of subjects: 469
Study 15878000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 301
Study 15878000 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 301
Study 11328289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy (third block of late intensification)
Number of subjects: 2090
Study 11328289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy
Number of subjects: 2090
Study 11328289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not randomized to the third block)
Number of subjects: 2090
Study 9617650 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofeedback training
Number of subjects: 0
Study 7938915 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant work rate exercise (CWE) at 76% of maximum work rate
Number of subjects: 10
Study 7938915 — intervention group
Group type: COMPARATOR
Intervention: Maximal incremental exercise (MIE)
Number of subjects: 10
Study 3282214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (CAZ)
Number of subjects: 206
Study 3282214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime + Vancomycin (CAZ + vancomycin)
Number of subjects: 206
Study 3282214 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin, Carbenicillin and Gentamicin (KCG)
Number of subjects: 206
Study 3282214 — intervention group
Group type: COMPARATOR
Intervention: KCG
Number of subjects: 206
Study 3282214 — intervention group
Group type: EXPERIMENTAL
Intervention: CAZ or CAZ + vancomycin
Number of subjects: 206
Study 27911988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (25-50 mg)
Number of subjects: 148
Study 27911988 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (2.5-5 mg)
Number of subjects: 148
Study 27658130 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (2.4 g daily for 1 month)
Number of subjects: 39
Study 24209423 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (organisational, environmental with height-adjustable workstations, and individual behavioural strategies)
Number of subjects: 320
Study 24209423 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control group
Number of subjects: 320
Study 24209423 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 320
Study 20542324 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) using a rush protocol with roasted peanut for 7 days
Number of subjects: 23
Study 20542324 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 23
Study 18382682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy prediction measure
Number of subjects: 0
Study 18382682 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction calculation
Number of subjects: 0
Study 16203884 — intervention group
Group type: EXPERIMENTAL
Intervention: Open operative treatment
Number of subjects: 800
Study 16203884 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair
Number of subjects: 800
Study 16203884 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional brace postoperatively
Number of subjects: 800
Study 16203884 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 800
Study 12519844 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months; n = 8)
Number of subjects: 17
Study 12519844 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol-cyproterone acetate (EE-CA; n = 9)
Number of subjects: 17
Study 10930893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg b.d per 7 days)
Number of subjects: 34
Study 10930893 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal (400 mg b.d per 7 days)
Number of subjects: 34
Study 8980155 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine
Number of subjects: 0
Study 8980155 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine
Number of subjects: 0
Study 1426824 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 to 2 mg IV) alone
Number of subjects: 19
Study 1426824 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 to 2 mg IV) combined with nitroglycerin infusion (25 micrograms/min)
Number of subjects: 19
Study 1426824 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin alone
Number of subjects: 19
Study 6140440 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption (up to 80 g daily)
Number of subjects: 16
Study 6140440 — intervention group
Group type: EXPERIMENTAL
Intervention: No alcohol for 4 days
Number of subjects: 16
Study 6140440 — intervention group
Group type: EXPERIMENTAL
Intervention: No alcohol for the first 3 days, then resumed alcohol consumption from day 4 to 7
Number of subjects: 16
Study 31035190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/day at bedtime)
Number of subjects: 40
Study 31035190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29025064 — intervention group
Group type: COMPARATOR
Intervention: Cholera vaccination only
Number of subjects: 429995
Study 29025064 — intervention group
Group type: COMPARATOR
Intervention: Cholera vaccination plus behaviour change (promotion of hand-washing with soap plus drinking water chlorination)
Number of subjects: 429995
Study 29025064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429995
Study 25472768 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (long/intermediate acting)
Number of subjects: 211
Study 25472768 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (premixed)
Number of subjects: 211
Study 25472768 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (basal-bolus)
Number of subjects: 211
Study 25472768 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 211
Study 23434503 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to aripiprazole
Number of subjects: 187
Study 23434503 — intervention group
Group type: COMPARATOR
Intervention: Stay on olanzapine, quetiapine, or risperidone
Number of subjects: 187
Study 19549615 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric loading exercises (ELE)
Number of subjects: 43
Study 19549615 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy injections of hypertonic glucose with lignocaine
Number of subjects: 43
Study 19549615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (ELE + prolotherapy)
Number of subjects: 43
Study 19165197 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficient mismatch repair (pMMR)
Number of subjects: 820
Study 19165197 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient mismatch repair (dMMR) caused by hypermethylation of the MLH1 promoter
Number of subjects: 820
Study 19165197 — intervention group
Group type: EXPERIMENTAL
Intervention: Total deficient mismatch repair (dMMR)
Number of subjects: 820
Study 16696522 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 44
Study 16696522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 microg)
Number of subjects: 44
Study 16696522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12689948 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Number of subjects: 30
Study 12689948 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 30
Study 10844388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial ejection force (AEF) in patients with SLE and RA
Number of subjects: 37
Study 10844388 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 40) matched for gender and age
Number of subjects: 37
Study 8945112 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith and Nephew Roylan D-Ring orthosis
Number of subjects: 36
Study 8945112 — intervention group
Group type: EXPERIMENTAL
Intervention: Other 2 commercial wrist extensor orthoses
Number of subjects: 36
Study 8945112 — intervention group
Group type: COMPARATOR
Intervention: All 3 commercial orthoses
Number of subjects: 36
Study 1932838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in post-menopausal patients (ER-negative)
Number of subjects: 0
Study 1932838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment in post-menopausal patients (ER-positive)
Number of subjects: 0
Study 1932838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (oophorectomy + tamoxifen) in pre-menopausal patients
Number of subjects: 0
Study 1932838 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 0
Study 6173514 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine infusion after placebo
Number of subjects: 6
Study 6173514 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine infusion after prazosin (alpha 1-blocker)
Number of subjects: 6
Study 6173514 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine infusion after oxprenolol (nonselective beta-blocker)
Number of subjects: 6
Study 6173514 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine infusion after prazosin and oxprenolol pretreatment
Number of subjects: 6
Study 6593309 — intervention group
Group type: EXPERIMENTAL
Intervention: 4'‐epi‐DX
Number of subjects: 8
Study 6593309 — intervention group
Group type: COMPARATOR
Intervention: DX
Number of subjects: 8
Study 29984691 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Oral Hygiene Advice (OHA)
Number of subjects: 1877
Study 29984691 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly Periodontal Instrumentation (PI)
Number of subjects: 1877
Study 29984691 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-monthly PI
Number of subjects: 1877
Study 29984691 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly PI
Number of subjects: 1877
Study 29984691 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised OHA with 6-monthly PI
Number of subjects: 1877
Study 29984691 — intervention group
Group type: COMPARATOR
Intervention: No PI with Personalised OHA
Number of subjects: 1877
Study 26679763 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2.2 g/day)
Number of subjects: 71
Study 26679763 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 71
Study 24965494 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 186
Study 24965494 — intervention group
Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 186
Study 23077137 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100-mg administered on Day 5 of a 7 day course of simvastatin 80-mg once daily
Number of subjects: 10
Study 23077137 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100-mg alone
Number of subjects: 10
Study 20889472 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who reported binge eating prior to or during treatment
Number of subjects: 186
Study 20889472 — intervention group
Group type: COMPARATOR
Intervention: Participants without binge eating
Number of subjects: 186
Study 20889472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group that experienced an emergence of binge eating
Number of subjects: 186
Study 18565950 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal cigarette smoke exposure
Number of subjects: 22
Study 18565950 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsmoking mothers)
Number of subjects: 22
Study 16496813 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol (n=93)
Number of subjects: 189
Study 16496813 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (n=96)
Number of subjects: 189
Study 16496813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 189
Study 12536245 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect radionuclide cystography (IRNC) using technetium‐99m diethylene triamine penta‐acetate (DTPA) with a dosage of 37 MBq/10 kg body weight.
Number of subjects: 74
Study 12536245 — intervention group
Group type: EXPERIMENTAL
Intervention: IRNC
Number of subjects: 74
Study 10532438 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost, 0.005%, 1 drop per day in each eye
Number of subjects: 24
Study 10532438 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 drop per day in each eye
Number of subjects: 24
Study 8896777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (2500 lx) for 2 hours daily for 1 week
Number of subjects: 34
Study 8896777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim red light (50 lx) for 2 hours daily for 1 week
Number of subjects: 34
Study 8896777 — intervention group
Group type: COMPARATOR
Intervention: Bright and dim light treatment
Number of subjects: 34
Study 8896777 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls receiving bright or dim light
Number of subjects: 34
Study 1676467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60,000 retinol equivalents every 4 months)
Number of subjects: 28630
Study 1676467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 retinol equivalents)
Number of subjects: 28630
Study 6630409 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mixed meal
Number of subjects: 7
Study 6630409 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meals
Number of subjects: 7
Study 6630409 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meals
Number of subjects: 7
Study 6630409 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine and L-tryptophan
Number of subjects: 7
Study 6630409 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 7
Study 6630409 — intervention group
Group type: COMPARATOR
Intervention: Prior receptor blockade with naloxone and atropine
Number of subjects: 7
Study 30366712 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (II) training
Number of subjects: 42
Study 30366712 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study 29490895 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital interventions for reducing hazardous and harmful alcohol consumption
Number of subjects: 41
Study 26660041 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% ethanol/4% sodium citrate
Number of subjects: 40
Study 26660041 — intervention group
Group type: COMPARATOR
Intervention: heparin 1000 units/mL
Number of subjects: 40
Study 24933232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass)
Number of subjects: 150
Study 24933232 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donors (control group)
Number of subjects: 150
Study 21816443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (37% energy from fat and 50% from carbohydrates)
Number of subjects: 12
Study 21816443 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (25% energy from fat and 62% from carbohydrates)
Number of subjects: 12
Study 20837894 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1232
Study 20837894 — intervention group
Group type: COMPARATOR
Intervention: Non-ICD medical therapy
Number of subjects: 1232
Study 17663103 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle retention at Baihui (GV 20) for 8 h and electroacupuncture at local points
Number of subjects: 120
Study 17663103 — intervention group
Group type: COMPARATOR
Intervention: Needle retention at Baihui (GV 20) for 30 min and electroacupuncture at local points
Number of subjects: 120
Study 16105001 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer sensor device
Number of subjects: 1245
Study 16105001 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric sensor
Number of subjects: 1245
Study 16105001 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended sensor
Number of subjects: 1245
Study 12810740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 600
Study 12810740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 600
Study 10418644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 30 mg/kg i.v. (repeated after 6 hours)
Number of subjects: 100
Study 10418644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.5 mg/kg i.v. (max. 40 mg)
Number of subjects: 100
Study 10418644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propacetamol and tenoxicam
Number of subjects: 100
Study 10418644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7737552 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole once daily
Number of subjects: 193
Study 7737552 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily
Number of subjects: 193
Study 7737552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1975448 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 71
Study 1975448 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study 1975448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 6117301 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam in oil (Diazemuls)
Number of subjects: 100
Study 6117301 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Dormicum)
Number of subjects: 100
Study 30968815 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water intake among pilgrims over 40 years of age (89.5%) compared to those under 40 years (76.5%)
Number of subjects: 412
Study 30968815 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cotton clothes among those aware of Mecca's weather (51.8%) compared to those unaware (36.0%)
Number of subjects: 412
Study 30968815 — intervention group
Group type: EXPERIMENTAL
Intervention: Going out at noon time among educated pilgrims (7.3%) compared to those with lower education (15.4%)
Number of subjects: 412
Study 28039245 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg i.v.
Number of subjects: 94
Study 28039245 — intervention group
Group type: EXPERIMENTAL
Intervention: chewing gum
Number of subjects: 94
Study 25967705 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 100
Study 25967705 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery (Control)
Number of subjects: 100
Study 23622912 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal eGFR (≥90 mL/min)
Number of subjects: 942
Study 23622912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild CKD (60-89 mL/min)
Number of subjects: 942